Advertisement
Advertisement

NBIX

NBIX logo

Neurocrine Biosciences Inc

141.23
USD
Sponsored
+3.30
+2.39%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

141.32

+0.09
+0.07%

NBIX Earnings Reports

Positive Surprise Ratio

NBIX beat 16 of 39 last estimates.

41%

Next Report

Next Week
Date of Next Report
Feb 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$810.65M
/
$1.94
Implied change from Q3 25 (Revenue/ EPS)
+1.98%
/
-4.90%
Implied change from Q4 24 (Revenue/ EPS)
+29.15%
/
+94.00%

Neurocrine Biosciences Inc earnings per share and revenue

On Oct 28, 2025, NBIX reported earnings of 2.04 USD per share (EPS) for Q3 25, beating the estimate of 1.61 USD, resulting in a 26.10% surprise. Revenue reached 794.90 million, compared to an expected 761.45 million, with a 4.39% difference. The market reacted with a -6.35% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 30 analysts forecast an EPS of 1.94 USD, with revenue projected to reach 810.65 million USD, implying an decrease of -4.90% EPS, and increase of 1.98% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Neurocrine Biosciences Inc reported EPS of $2.04, beating estimates by 26.1%, and revenue of $794.90M, 4.39% above expectations.
The stock price moved down -6.35%, changed from $147.38 before the earnings release to $138.02 the day after.
The next earning report is scheduled for Feb 11, 2026.
Based on 30 analysts, Neurocrine Biosciences Inc is expected to report EPS of $1.94 and revenue of $810.65M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement